Task order: further testing of a multi-peptide kras vaccine for pancreatic cancer prevention
Ended Awarded Last action
- Contract number
- 75N91020F00001
- Awardee
-
University Of Oklahoma UEI GY8NMUZQXVS7 Part of University Of Oklahoma
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $493,001
Award facts
- Opportunity
- Contract value 100% obligated
- $493,001.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Oklahoma City, OK 73126, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $493,001 |
About this award
The University of Oklahoma is the prime contractor for this $493,001 firm fixed price delivery order against the PREVENT Preclinical Drug Development Program IDIQ vehicle held by the National Cancer Institute. The order calls for further testing of a multi-peptide KRAS vaccine for pancreatic cancer prevention, with objectives to determine efficacy in a genetically engineered mouse model and evaluate immune responses to establish correlates of antitumor protection. Major subcontractors include Houston Methodist Hospital to conduct the mouse model study and the Medical College of Wisconsin to further test the vaccine's efficacy. Funding is provided by the National Institutes of Health's National Cancer Institute to advance the vaccine's development under the PREVENT program prior to potential human clinical trials.
Quick answers
Who was awarded contract 75N91020F00001?
75N91020F00001 was awarded to University Of Oklahoma by National Cancer Institute (National Institutes of Health) on February 21, 2020.
How much is contract 75N91020F00001 worth?
The government has obligated $493,001 on 75N91020F00001.
Is contract 75N91020F00001 an order under another contract?
Yes. 75N91020F00001 is a delivery order under 75N91019D00020, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91020F00001 competed?
The extent of competition for 75N91020F00001 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award